tbuckley/cabot-search huggingface dataset:
One third of US women travel more than 25 miles for an abortion
Authors: J. H. Tanne
Journal: BMJ (2013)

In 2008 more than one third of women in the United States seeking abortions traveled more than 25 miles for care. Today the number is probably higher, says the Guttmacher Institute, which works to advance sexual and reproductive health in the US and around the world.

A study by the institute is the first to report how far US women seeking abortions traveled.1 Previous studies relied on estimates by abortion providers. The institute said that the study would serve as a baseline for trends, since states had placed more restrictions on abortion in recent years.

The study surveyed a national …
Response to Letter Regarding Article, “Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin”
Authors: Ammar Majeed, Hun-Gyu Hwang, Stuart J. Connolly, John W. Eikelboom, Michael D. Ezekowitz, Lars Wallentin, Martina Brueckmann, Mandy Fraessdorf, Salim Yusuf, Sam Schulman
Journal: Circulation (2014)
Native American Medicine
Authors: Morgan Martin
Journal: JAMA (1981)

THE AMERICAN INDIAN medicine man uses traditional ways of healing that are curiously modern, and from which his posttraditional medical brethren can learn. (To say medicine man is misleading, because many traditional Indian therapists are women.1,2Indeed, the most powerful medicine people are women, which is easy to appreciate when one realizes that most tribes are matriarchal, and in many, the husband takes the wife's name.)  To understand traditional practices one must understand that their context is the society and culture.3The Indian believes that everything has a spirit: earth, her animals, trees, roots, and rocks, as well as elements such as lightning and wind. The result is that the Indian is part of all that is around him; he has a sense of brotherhood with all things. This shows in his respect for the streams he crosses, the trees he takes, the roots he gathers, and the
Neural network model prognosis in patients with heart failure and acute myocardial infarction after previous coronary artery bypass surgery
Authors: P. Mitrovic, G. Stojanovski, Z. Vasiljevic, B. Stefanovic, J. Perunicic, I. Mrdovic, G. Matic, T. Jozic, D. Rajic, B. Milentijevic
Journal: European Journal of Heart Failure (2000)
763 ENTECAVIR EFFECT ON LIVER FUNCTION IN FIELD PRACTICE: INTERIM ANALYSIS OF THE ITALIAN Master-Entas COHORT STUDY OF PATIENTS WITH CHRONIC HEPATITIS B
Authors: A. Alfieri, M. Fasano, G. Brancaccio, T. Santantonio, F. Malfatti, A. Marzano, F. Bronte, G. Caccamo, S. Fagiuoli, F. Morisco, E. Petrelli, G. Svegliati Baroni, G. Labbadia, G. Verucchi, A.M. Ippolito, G.B. Pinzello, A. Montineri, F. Vinelli, M. Massari, L. Nosotti, G. Galati, G. Missale
Journal: Journal of Hepatology (2013)
Long‐term outcome of pomalidomide therapy in myelofibrosis
Authors: Kebede H. Begna, Animesh Pardanani, Ruben Mesa, Mark R. Litzow, William J. Hogan, Curtis A. Hanson, Ayalew Tefferi
Journal: American Journal of Hematology (2011)

Abstract Ninety‐four Mayo Clinic patients with myelofibrosis (MF) participated in two consecutive clinical trials of pomalidomide (0.5–3.5 mg/day), with or without prednisone. Overall anemia response was 27% and increased to 53% in JAK2 V617F‐positive patients with &lt;10 cm palpable splenomegaly and &lt;5% circulating blasts; response rate was 0% in mutation‐negative patients with either ≥10 cm splenomegaly or ≥5% circulating blasts ( P = 0.0001). Median duration of anemia response was 16 months. Treatment effect on splenomegaly was negligible. To date, pomalidomide therapy has been discontinued in 86 (91%) patients at a rate of 68% at 1 year and 89% at 2 years. Grade 1 sensory neuropathy developed in 4 (13%) of 30 patients treated for ≥1 year. Risk‐adjusted survival in pomalidomide‐treated primary MF patients ( n = 72) was similar to their counterparts not exposed to the drug ( n = 471; P = 0.19). Long‐term follow‐up of pomalidomide treatment in MF reveals palliative value for a select group of patients and treatment‐emergent sensory neuropathy. Am. J. Hematol. 2012. © 2011 Wiley Periodicals, Inc.
Lentiviral Vectors for T-cell Suicide Gene Therapy: Preservation of T-cell Effector Function After Cytokine-mediated Transduction
Authors: Waseem Qasim, Taylor Mackey, Jo Sinclair, Ilenia Chatziandreou, Christine Kinnon, Adrian J Thrasher, H Bobby Gaspar
Journal: Molecular Therapy (2007)

Retroviral transfer of the Herpes Simplex thymidine kinase (HSVTK) suicide gene to donor T cells has been used as a safety strategy against graft-versus-host disease following allogeneic stem cell transplantation. The feasibility of this strategy in human studies has been demonstrated, but a number of limitations have become apparent. Preactivation of donor lymphocytes using mitogens or monoclonal antibodies is essential for retroviral transduction, but can compromise subsequent T-cell function in vivo. We report the application of lentiviral vectors for transduction of T cells in cytokine culture, without activation through the T-cell receptor. Using vectors encoding either enhanced green fluorescent protein or a truncated CD34/mutant HSVTK fusion selection/suicide construct, we investigated the properties of T cells after gene modification. We found that following cytokine stimulation, a fraction of T cells undergoes division, and transgene expression occurred predominantly in these cells. Antiviral and alloreactive responses were preserved in these populations, and in contrast to fully activated T cells, there was minimal perturbation of regulatory T-cell numbers. We conclude that the use of interleukin-7 for lentiviral transduction offers the greatest potential for gene transfer to T cells without loss of function, and is favored for the clinical production of suicide gene modified T cells.
Identification of a novel subset of human circulating memory CD4+ T cells that produce both IL-17A and IL-4
Authors: Lorenzo Cosmi, Laura Maggi, Veronica Santarlasci, Manuela Capone, Elisa Cardilicchia, Francesca Frosali, Valentina Querci, Roberta Angeli, Andrea Matucci, Massimiliano Fambrini, Francesco Liotta, Paola Parronchi, Enrico Maggi, Sergio Romagnani, Francesco Annunziato
Journal: Journal of Allergy and Clinical Immunology (2010)
Library of Medical Computer Programs
Authors: Robert S. Wigton, Robert Panzer
Journal: Annals of Internal Medicine (1984)

Letters and Corrections1 April 1984Library of Medical Computer ProgramsROBERT S. WIGTON, M.D., ROBERT PANZER, M.D.ROBERT S. WIGTON, M.D., ROBERT PANZER, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-100-4-611_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: The Combined Computer Users Groups of The Society for Research and Education in Primary Care Internal Medicine (SREPCIM) and the Society for Medical Decision Making are establishing a library for medical software exchange. A listing of donated computer programs will be available this spring. There will be a nominal charge for programs to cover costs and to make the library self supporting. We encourage donations of programs related to medical therapy, diagnosis, decision making, statistics, and data management. There will be incentives for software contributions and user feedback. Four members of the University of Rochester School of... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: ROBERT S. WIGTON, M.D.; ROBERT PANZER, M.D.Affiliations: Department of Medicine University of Nebraska College of Medicine 42nd and Dewey Avenue; Omaha, NE 68105Department of Medicine University of Rochester School of Medicine and Dentistry 601 Elmwood Avenue; Rochester, NY 14642 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 April 1984Volume 100, Issue 4Page: 611-611KeywordsComputer softwareData managementDecision makingLibrariesMedical educationMotivationSoftware tools ePublished: 1 December 2008 Issue Published: 1 April 1984 PDF downloadLoading ...
Why We Still Need Randomized Trials to Compare Effectiveness
Authors: Laura Mauri
Journal: New England Journal of Medicine (2012)

Over the past 20 years, there have been 12 randomized trials in which the revascularization strategies of coronary-artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) have been compared, against the background of advances in both fields. Percutaneous treatment of multiple vessels has become more feasible, more durable, and more common, and yet the most contemporary randomized trial comparing PCI with CABG showed that CABG remained the preferred strategy for the treatment of patients with three-vessel coronary artery disease, owing primarily to a greater need for second procedures after PCI.1 Weintraub and colleagues2 now present the results of the American . . .
Gastric Intestinal Vascular Ectasia Syndrome: Findings on Capsule Endoscopy
Authors: S. Tang, S. Zanati, G. Kandel, N. Marcon, P. Kortan
Journal: Endoscopy (2005)

Gastric antral vascular ectasia (GAVE) syndrome has been recognized as an important cause of gastrointestinal hemorrhage [1] [2]. Histopathologically, GAVE is characterized by superficial fibromuscular hyperplasia of the gastric antral mucosa, with capillary ectasia and microvascular thrombosis in the lamina propria. Although it is helpful to make a pathological diagnosis, the most reliable means of diagnosing GAVE and other areas of angioectasia in the gastrointestinal tract is by direct endoscopic visualization [2]. Since GAVE was first described, there have been several reports of patients with similar endoscopic findings in other regions of the gastrointestinal tract, including the cardia [3], duodenum [4], colon [5] [6], and rectum [7]. Terms such as “watermelon cecum”, “watermelon colon”, and “watermelon rectum” have been coined to describe such lesions.
A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis
Authors: Laura N. Bull, Michiel J.T. van Eijk, Ludmila Pawlikowska, Joseph A. DeYoung, Jenneke A. Juijn, Mira Liao, Leo W.J. Klomp, Noureddine Lomri, Ruud Berger, Bruce R. Scharschmidt, Alexander S. Knisely, Roderick H.J. Houwen, Nelson B. Freimer
Journal: Nature Genetics (1998)
MYOSITIS OSSIFICANS TRAUMATICA
Authors: William E. Stevens
Journal: JAMA (1913)

Myositis ossificans is a pathologic condition characterized by the formation of bone in or between the muscles. There are two forms, the progressive, in which ossification successively occurs in many parts of the muscular system, and the traumatic, which is limited to one muscle or group of muscles. The following is an unusual case of the latter type: The patient is a sheet-metal worker, aged 50; a native of Germany. His father died at the age of 60 after having suffered from a cough for years. The family history is otherwise negative. The patient has never been sick except for an attack of mumps fifteen years ago and occasional colds of short duration. He denies venereal disease and has used very little liquor. In 1869 when 7 years old he was struck on the calf of the leg by a heavy timber. After this injury he began to walk on
ACTION OF THE GOLDEN BELT DISTRICT MEDICAL SOCIETY OF KANSAS.
Authors: John C. Sundberg
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 4157: DACH1 Inhibited proliferation and tumor growth of lung adenocarcinoma cells
Authors: Zhaoming Li, Shaoxin Cai, Junbo Hu, Richard G. Pestell, Kongming Wu
Journal: Cancer Research (2012)

Abstract Lung cancer is the leading cause of cancer death worldwide. A key driver to the proliferation of lung cancer includes increased activity of the gene encoding the epidermal growth factor receptor (EGFR) and mutation of K-ras oncogene. Target therapies through small molecules to inhibit the tyrosine kinase domain of EGFR (Gefitinib) or monoclonal antibody to EGFR (Cetuximab) have demonstrated clinical benefit. Unfortunately, development of resistance to those treatments occurs in most patients within one year. Studies of the hyperactive EGFR in drosophila identified a genetic inhibitor of EGFR signaling, known as dachshund (dac). Activate ras inhibits DACH1 expression in malignant peripheral nerve sheath tumor. Dachshund can activate or represses transcription, and regulates cell proliferation and differentiation in multiple context-dependent manners. Our studies have proved that DACH1, human homolog of dac, functions as a potential tumor suppressor of breast and prostate cancer. Expression of DACH1 is lost during cancer progression and re-expression of DACH1 gene inhibited cellular proliferation, migration and tumor formation. The expression levels and the role of DACH1 in lung cancer are largely unknown. As both EGFR and Ras signaling interact with DACH1, we hypotheses that loss of endogenous DACH1 may contribute to the lung tumorigenesis. The mRNA expression of DACH1 was decreased in lung adenocarcinoma compared with normal lung tissues. Ectopic expression of DACH1 by stably transduction inhibited cellular proliferation of lung cancer cell lines A549 and SKLU, cell cycle progression and clone formation rate in contact-dependent and -independent growth. ELISA using conditional medium from A549 cells expressing vector control or DACH1 demonstrated remarkable inhibition of secreting factors, such as CXCL1, CXCL2, CXCL5 and CXCL8. Those chemokines have already been proved to positively regulating angiogenesis and proliferation. To test in vivo tumorigenesis, 2x106 A549 cells expressing DACH1 or vector control were injected subcutaneously into nude mouse and tumor size was monitored weekly. Tumor growth was dramatically blocked by DACH1. Tumor weight was 297.8 ± 38.6mg for vector control and 31 ± 6.1mg for cells expressing DACH1(p value &amp;lt;0.001). Importantly, over-expression of CXCL5 can partly rescue tumor growth inhibition by DACH1 in A549 cells. Together, our study demonstrated that DACH1 is a potentially tumor suppressor of lung cancer though repression of chemokines secretion. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4157. doi:1538-7445.AM2012-4157
The polio eradication end game: what it means for Europe
Authors: D Heymann, Q Ahmed
Journal: Eurosurveillance (2014)

Preview this article: The polio eradication end game: what it means for Europe, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/19/7/art20702-en-1.gif
Effect of moderate dose of alcohol with evening meal on fibrinolytic factors
Authors: H F J Hendriks, J Veenstra, E J M V.-T. Wierik, G Shaafsma, C Kluft
Journal: BMJ (1994)

<h3>Abstract</h3> <b>Objectives</b>: To evaluate the effects of moderate consumption of alcoholic beverages on the fibrinolytic system and to assess whether these effects could help explain the relation between moderate alcohol consumption and reduced coronary heart disease. <b>Design</b>: Four treatments were allocated in a randomised controlled order on four days over a period of 11 days. <b>Setting</b>: Metabolic ward of research institute. <b>Subjects</b>: Eight white healthy middle aged men. <b>Interventions</b>: Subjects were provided with food for the 11 days. On the four study days mineral water or 40 g of alcohol in the form of beer, wine, or spirits was consumed at dinner early in the evening. <b>Main outcome measures</b>: Plasminogen activator inhibitor activity, tissue type plasminogen activator antigen, and tissue type plasminogen activator activity one hour before and one, three, five, nine, and 13 hours after dinner with mineral water or alcoholic beverages. <b>Results</b>: After dinner with alcohol plasminogen activator inhibitor activity rose from 53 (SD 19)% to a maximum of 667 (283%) five hours after dinner (P&lt;0.001). Tissue type plasminogen activator antigen levels rose from 5.3 (2.2) μg/l to a maximum of 10.8 (3.8) μg/l nine hours after dinner with alcohol (P&lt;0.001). Plasminogen activator activity was reduced in the postprandial period (from 1387 (483) IU/l to 323 (288) IU/l five hours after eating; P&lt;0.001) but was higher than normal early the next morning (1516 (809) IU/l after alcohol, 779 (516) IU/l after water; P=0.04). <b>Conclusion</b>: Moderate alcohol consumption with dinner affects plasminogen activator inhibitor activity, plasminogen activator antigen level, and tissue type plasminogen activator activity temporarily. The effects observed in the early morning are consistent with a decrease in risk of coronary heart disease in moderate drinkers.
Modulation of endothelial Ca2+-activated K+ channels by oxidized LDL and its contribution to endothelial proliferation
Authors: C Kuhlmann
Journal: Cardiovascular Research (2003)

Oxidized low-density lipoprotein (oxLDL) plays an important role in causing endothelial dysfunction and initiating atherosclerosis. Some of the endothelial functions have been shown to be modulated by changes in cellular electrophysiological properties. Therefore, we analysed the effect of oxLDL on endothelial Ca(2+)-activated K(+) channels (BK(Ca)) and its contribution to oxLDL-mediated changes of proliferation and syntheses of nitric oxide (NO).The patch-clamp technique was used to study the behavior of BK(Ca) in human endothelial cells of umbilical cord veins (HUVEC). Changes of intracellular Ca(2+) were measured by means of Fura-2 imaging. Cell counts and [3H]-thymidine incorporation were used to analyse endothelial proliferation. Synthesis of NO was measured by means of [3H]-cGMP radioimmunoassay.oxLDL (10 microg/ml) caused a significant increase of BK(Ca) activity, whereas preincubation of HUVEC with an antibody against the lectin-like-oxLDL-receptor-1 (LOX-1) abolished BK(Ca) activation. Fura-2 measurements revealed a biphasic increase of intracellular Ca(2+) after application of the atherogenic lipid. Endothelial proliferation was significantly increased by oxLDL. The highly selective BK(Ca) inhibitor iberiotoxin (100 nmol/l IBX) blocked this proliferative response. Acetylcholine-induced NO synthesis was significantly decreased by IBX. Interestingly, oxLDL significantly decreased acetylcholine-induced NO synthesis if the production of superoxide was not blocked by antisense oligonucleotides against the NAD(P)H-oxidase.Our data demonstrate that oxLDL activates BK(Ca), which plays an important role in oxLDL-mediated endothelial proliferation. Acetylcholine-induced NO synthesis is modulated by BK(Ca), whereas the reduction of acetylcholine-induced NO-synthesis by oxLDL is related to an increase in superoxide production.
Adverse Outcomes of Interrupted Precordial Compression During Automated Defibrillation
Authors: Ting Yu, Max Harry Weil, Wanchun Tang, Shijie Sun, Kada Klouche, Heitor Povoas, Joe Bisera
Journal: Circulation (2002)

Current versions of automated external defibrillators (AEDs) require frequent stopping of chest compression for rhythm analyses and capacity charging. The present study was undertaken to evaluate the effects of these interruptions during the operation of AEDs.Ventricular fibrillation was electrically induced in 20 male domestic swine weighing between 37.5 and 43 kg that were untreated for 7 minutes before CPR was started. Defibrillation was attempted with up to 3 sequential 150-J biphasic shocks, but each was preceded by 3-, 10-, 15-, or 20-second interruptions of chest compression. The interruptions corresponded to those that were mandated by commercially marketed AEDs for rhythm analyses and capacitor charge. The sequence of up to 3 electrical shocks and delays were repeated at 1-minute intervals until the animals were successfully resuscitated or for a total of 15 minutes. Spontaneous circulation was restored in each of 5 animals in which precordial compression was delayed for 3 seconds before the delivery of the first and subsequent shocks but in none of the animals in which the delay was >15 seconds before the delivery of the first and subsequent shocks. Longer intervals of CPR interventions were required, and there was correspondingly greater failure of resuscitation in close relationship to increasing delays. The durations of interruptions were inversely related to the durations of subthreshold levels of coronary perfusion pressure. Postresuscitation arterial pressure and left ventricular ejection fraction were more severely impaired with increasing delays.Interruptions of precordial compression for rhythm analyses that exceed 15 seconds before each shock compromise the outcome of CPR and increase the severity of postresuscitation myocardial dysfunction.
Mechanisms of Tissue Uptake and Retention in Zotarolimus-Coated Balloon Therapy
Authors: Vijaya B. Kolachalama, Stephen D. Pacetti, Joseph W. Franses, John J. Stankus, Hugh Q. Zhao, Tarek Shazly, Alexander Nikanorov, Lewis B. Schwartz, Abraham R. Tzafriri, Elazer R. Edelman
Journal: Circulation (2013)

Background— Drug-coated balloons are increasingly used for peripheral vascular disease, and, yet, mechanisms of tissue uptake and retention remain poorly characterized. Most systems to date have used paclitaxel, touting its propensity to associate with various excipients that can optimize its transfer and retention. We examined zotarolimus pharmacokinetics. Methods and Results— Animal studies, bench-top experiments, and computational modeling were integrated to quantify arterial distribution after zotarolimus-coated balloon use. Drug diffusivity and binding parameters for use in computational modeling were estimated from the kinetics of zotarolimus uptake into excised porcine femoral artery specimens immersed in radiolabeled drug solutions. Like paclitaxel, zotarolimus exhibited high partitioning into the arterial wall. Exposure of intimal tissue to drug revealed differential distribution patterns, with zotarolimus concentration decreasing with transmural depth as opposed to the multiple peaks displayed by paclitaxel. Drug release kinetics was measured by inflating zotarolimus-coated balloons in whole blood. In vivo drug uptake in swine arteries increased with inflation time but not with balloon size. Simulations coupling transmural diffusion and reversible binding to tissue proteins predicted arterial distribution that correlated with in vivo uptake. Diffusion governed drug distribution soon after balloon expansion, but binding determined drug retention. Conclusions— A large bolus of zotarolimus releases during balloon inflation, some of which pervades the tissue, and a fraction of the remaining drug adheres to the tissue–lumen interface. As a result, the duration of delivery modulates tissue uptake where diffusion and reversible binding to tissue proteins determine drug transport and retention, respectively.